OXYCODONE HYDROCHLORIDE, Tablets USP, CII, 15 mg, & 30 mg, Rx only

/OXYCODONE HYDROCHLORIDE, Tablets USP, CII, 15 mg, & 30 mg, Rx only
OXYCODONE HYDROCHLORIDE, Tablets USP, CII, 15 mg, & 30 mg, Rx only2018-09-06T09:12:40+00:00

Prescription Drug Name:

OXYCODONE HYDROCHLORIDE, Tablets USP, CII, 15 mg, & 30 mg, Rx only

ID:

697f587f-f37e-4ed2-9d54-dd346766346c

Code:

34391-3

DESCRIPTION


id: a804d74f-e7e6-44c5-b06a-7f511a0cdfef
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Oxycodone Hydrochloride Tablets USP are an opioid analgesic. Each tablet for oral administration contains 5 mg, 15 mg, or 30 mg of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. Oxycodone hydrochloride dissolves in water (1 g in 6 to 7 mL) and is considered slightly soluble in alcohol (octanol water partition coefficient is 0.7). Chemically, oxycodone hydrochloride is 4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride and has the following structural formula:

The tablets contain the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, stearic acid, D&C Yellow No. 10 (15 mg tablet), and FD&C Blue No. 2 (15 mg and 30 mg tablets). The 5 mg, 15 mg and 30 mg tablets contain the equivalent of 4.5 mg, 13.5 mg and 27.0 mg, respectively, of oxycodone free base.

INDICATIONS AND USAGE


id: 830f277a-b44c-41af-912d-e14d89ee27aa
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Oxycodone hydrochloride tablets are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.

CONTRAINDICATIONS


id: 76b8b1f4-4b64-4f91-9bd3-1ce5059f6712
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Oxycodone hydrochloride tablets are contraindicated in patients with known hypersensitivity to oxycodone, or in any situation where opioids are contraindicated. This includes patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial asthma or hypercarbia. Oxycodone hydrochloride tablets are contraindicated in any patient who has or is suspected of having paralytic ileus.

ADVERSE REACTIONS


id: 8c9879f9-a903-4ba7-a375-994a6e0aac4f
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Oxycodone hydrochloride tablets have been evaluated in open label clinical trials in patients with cancer and nonmalignant pain. Oxycodone hydrochloride tablets are associated with adverse experiences similar to those seen with other opioids. Serious adverse reactions that may be associated with oxycodone hydrochloride tablets therapy in clinical use are those observed with other opioid analgesics and include: respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock (see
OVERDOSAGE, WARNINGS ).
The less severe adverse events seen on initiation of therapy with oxycodone hydrochloride tablets are also typical opioid side effects. These events are dose dependent, and their frequency depends on the clinical setting, the patient’s level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid analgesia. The most frequent of these include nausea, constipation, vomiting, headache, and pruritus. In many cases the frequency of adverse events during initiation of opioid therapy may be minimized by careful individualization of starting dosage, slow titration and the avoidance of large rapid swings in plasma concentration of the opioid. Many of these adverse events will abate as therapy is continued and some degree of tolerance is developed, but others may be expected to remain throughout therapy. In all patients for whom dosing information was available (n=191) from the open-label and double-blind studies involving oxycodone hydrochloride tablets, the following adverse events were recorded in patients treated with oxycodone hydrochloride tablets with an incidence ≥ 3%. In descending order of frequency they were: nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia, and somnolence. The following adverse experiences occurred in less than 3% of patients involved in clinical trials with oxycodone:

DOSAGE AND ADMINISTRATION


id: 5c2bf0f6-1e89-48df-bbe7-317d5e3f44c2
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

Oxycodone hydrochloride tablets are intended for the management of moderate to severe pain in patients who require treatment with an oral opioid analgesic. The dose should be individually adjusted according to severity of pain, patient response and patient size. If the pain increases in severity, if analgesia is not adequate, or if tolerance occurs, a gradual increase in dosage may be required. Patients who have not been receiving opioid analgesics should be started on oxycodone hydrochloride tablets in a dosing range of 5 to 15 mg every 4 to 6 hours as needed for pain. The dose should be titrated based upon the individual patient’s response to their initial dose of oxycodone hydrochloride tablets. Patients with chronic pain should have their dosage given on an around-the-clock basis to prevent the reoccurrence of pain rather than treating the pain after it has occurred. This dose can then be adjusted to an acceptable level of analgesia taking into account side effects experienced by the patient. For control of severe chronic pain, oxycodone hydrochloride tablets should be administered on a regularly scheduled basis, every 4 to 6 hours, at the lowest dosage level that will achieve adequate analgesia. As with any potent opioid, it is critical to adjust the dosing regimen for each patient individually, taking into account the patient’s prior analgesic treatment experience. Although it is not possible to list every condition that is important to the selection of the initial dose of oxycodone hydrochloride tablets, attention should be given to: 1) the daily dose, potency, and characteristics of a pure agonist or mixed agonist/antagonist the patient has been taking previously, 2) the reliability of the relative potency estimate to calculate the dose of oxycodone needed, 3) the degree of opioid tolerance, 4) the general condition and medical status of the patient, and 5) the balance between pain control and adverse experiences.

HOW SUPPLIED


id: 12208331-241c-4fa8-91f0-5329a9e50e01
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Each Oxycodone Hydrochloride Tablet USP 15 mg is available as a light green round convex tablet with a on one side and “15” above a bisect on the other. Bottles of 45 …………………… NDC 66336-0470-45 Bottles of 180 …………………… NDC 66336-0470-62 Bottles of 120 …………………… NDC 66336-0470-94 Each Oxycodone Hydrochloride Tablet USP 30 mg is available as a light blue round convex tablet with a on one side and “30” above a bisect on the other. Bottles of 120 …………………… NDC 66336-0135-94

Package Label – Principal Display Panel – 15 mg Tablets


id: c844e8b9-e49e-4419-8e1f-8e44b67d0cfa
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

NDC 66336-0470-45 NDC 66336-0470-62 NDC 66336-0470-94 NDC 66336-0470-XX

Package Label – Principal Display Panel – 30 mg Tablets


id: e4c3ff9e-d898-4a2b-a6e7-b5e2b52cea94
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

NDC 66336-135-94 NDC 66336-135-XX